Dashboard
1
Poor Management Efficiency with a low ROCE of 5.00%
- The company has been able to generate a Return on Capital Employed (avg) of 5.00% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of -9.06% and Operating profit at 41.18% over the last 5 years
3
Positive results in Mar 25
4
With ROE of 11.86%, it has a fair valuation with a 3.24 Price to Book Value
5
Market Beating Performance
Stock DNA
Pharmaceuticals & Biotechnology
CNY 6,635 Million (Mid Cap)
27.00
NA
0.00%
-0.25
11.86%
3.24
Revenue and Profits:
Net Sales:
540 Million
(Quarterly Results - Jun 2025)
Net Profit:
75 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-5.01%
0%
-5.01%
6 Months
11.03%
0%
11.03%
1 Year
23.37%
0%
23.37%
2 Years
20.6%
0%
20.6%
3 Years
19.26%
0%
19.26%
4 Years
33.61%
0%
33.61%
5 Years
2.22%
0%
2.22%
Harbin Gloria Pharmaceuticals Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-9.06%
EBIT Growth (5y)
41.18%
EBIT to Interest (avg)
9.96
Debt to EBITDA (avg)
0.31
Net Debt to Equity (avg)
-0.27
Sales to Capital Employed (avg)
1.11
Tax Ratio
12.45%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.00%
ROE (avg)
4.75%
Valuation key factors
Factor
Value
P/E Ratio
27
Industry P/E
Price to Book Value
3.24
EV to EBIT
27.29
EV to EBITDA
19.45
EV to Capital Employed
3.99
EV to Sales
2.68
PEG Ratio
3.87
Dividend Yield
NA
ROCE (Latest)
14.63%
ROE (Latest)
11.86%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
540.50
542.60
-0.39%
Operating Profit (PBDIT) excl Other Income
86.20
80.40
7.21%
Interest
2.20
0.10
2,100.00%
Exceptional Items
5.00
3.60
38.89%
Consolidate Net Profit
75.50
61.90
21.97%
Operating Profit Margin (Excl OI)
117.60%
106.40%
1.12%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -0.39% vs -5.59% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 21.97% vs 21.85% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,406.90
2,589.90
-7.07%
Operating Profit (PBDIT) excl Other Income
312.00
275.30
13.33%
Interest
10.00
51.00
-80.39%
Exceptional Items
-16.30
-15.70
-3.82%
Consolidate Net Profit
242.50
128.70
88.42%
Operating Profit Margin (Excl OI)
91.70%
64.40%
2.73%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -7.07% vs -15.54% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 88.42% vs 144.46% in Dec 2023
About Harbin Gloria Pharmaceuticals Co., Ltd. 
Harbin Gloria Pharmaceuticals Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






